Facebook Pixel How India's Diabetes Crisis is Driving Med Devices Market | Bio Spectrum - business - Read this story on Magzter.com
Go Unlimited with Magzter GOLD

Go Unlimited with Magzter GOLD

Get unlimited access to 10,000+ magazines, newspapers and Premium stories for just

$149.99
 
$74.99/Year

Try GOLD - Free

How India's Diabetes Crisis is Driving Med Devices Market

Bio Spectrum

|

December 2025

A growing diabetic population in India is a blessing for the care devices market. Both Indian and global diabetes care devices have taken this growing demand for various devices, kits as an opportunity to expand their market share. But the scope in rural areas seems a bit challenging for various companies due to less awareness about the disease, affordability etc. Let's look at this growing diabetes care devices market.

- Sanjiv Das

How India's Diabetes Crisis is Driving Med Devices Market

With diabetes seeing an uptick and India being the Diabetes Capital of the World, the diabetes care devices market is experiencing robust growth. A GlobalData analysis reveals that India accounted for around 20 per cent of the Asia-Pacific (APAC) diabetes care devices market in 2024, driven by a confluence of factors, including a rapidly escalating diabetic population, increased diagnosis, rising disposable incomes, and the adoption of advanced diabetes management technologies.

According to Frost & Sullivan analysis, the Indian diabetes care devices market is currently estimated at $4.8 billion and will reach $7.7 billion in 2030 with a projected compounded annual growth rate (CAGR) of approximately 9 per cent for the projected period of 2026-2030.

The digital health platforms segment reflects its high growth potential and encompasses a range of interconnected technologies, services, and applications. Its key components are mobile health (mHealth) apps for medication nudges and diet and exercise logs, teleconsultation and remote patient monitoring packages, predictive analytics for personalised medicine, and patient data management software. The segment will experience rapid adoption, driven by India's high smartphone penetration, the government's initiatives like the India AI mission, and growing Internet connectivity.

Key growth drivers

Rising disease prevalence, increased health awareness, strategic partnerships in the private sector, technological advancements, insurance and corporate wellness inclusion, E-commerce and telehealth penetration. According to Frost and Sullivan, government initiatives such as Ayushman Bharat undertake population-based screening for non-communicable diseases like diabetes in individuals over 30 years of age by trained frontline workers, have helped the sector to flourish.

MORE STORIES FROM Bio Spectrum

Bio Spectrum

Biotium's new cell barcoding kit streamlines flow cytometry with single-tube multiplexing

Biotium, a leading provider of fluorescent reagents and kits for life science research, has announced the release of the ViaPlex 2-Color Cell Barcoding Kit.

time to read

1 min

May 2026

Bio Spectrum

Bio Spectrum

NATHEALTH names Dr Sangita Reddy as new President

NATHEALTH, an apex body representing the Indian healthcare industry, has announced Dr Sangita Reddy, Joint Managing Director, Apollo Hospitals Group, as its new President for FY 2026-2027.

time to read

1 min

May 2026

Bio Spectrum

Rs 4.51 Lakh Crore Health Push: How State Budgets Are Powering India's Next Healthcare Leap

In recent years, state health budgets have transformed from simple financial documents into strategic instruments for improving healthcare outcomes.

time to read

7 mins

May 2026

Bio Spectrum

WHO lays focus on simulation exercises to strengthen health emergency readiness

To support countries to prepare more systematically against emergencies, WHO has recently released new global guidance which enables countries to move beyond oneoff emergency drills and establish National Health Simulation Exercise Programmes (NHSEP).

time to read

1 min

May 2026

Bio Spectrum

Bio Spectrum

Akrivia Biosciences decodes breast cancer genomic heterogeneity

Akrivia Biosciences, a cancer genomics startup based in London and Mumbai, has announced a foundational scientific breakthrough that uncovers hidden organisation of cancer genomes, successfully decoding breast cancer genomic heterogeneity, a major bottleneck that has historically hindered the comprehensive understanding of tumour biology in patients.

time to read

1 min

May 2026

Bio Spectrum

Bio Spectrum

Integrating AI for Tech-driven Ayurveda

A promising trend emerging in 2026 is the integration of artificial intelligence (AI) into ayurveda, to not only make ayurveda more accessible and scalable but to also create opportunities to back up ayurveda with science and technology.

time to read

2 mins

May 2026

Bio Spectrum

ASPIRE BIONEST signs MoU with Indian Immunologicals to advance One Health Innovation

ASPIRE BIONEST, a life sciences incubation centre at the University of Hyderabad, has signed a strategic Memorandum of Understanding (MoU) with Indian Immunologicals Ltd. (IIL), a leading vaccine-focused biotechnology company, to advance innovation under the One Health framework.

time to read

1 min

May 2026

Bio Spectrum

MSD India and Smile Foundation award 50 scholarships to aspiring pharmacy students

MSD (known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada) in India has announced the awarding of scholarships to 50 students under its corporate social responsibility initiative 'Scholarship for Daughters' programme, a merit-based initiative aimed at supporting young women from underserved communities to pursue a Bachelor of Pharmacy degree at select accredited pharmacy colleges across India.

time to read

1 min

May 2026

Bio Spectrum

Bio Spectrum

Thermo Fisher launches integrated platform to accelerate biologics development

Thermo Fisher Scientific Inc. has announced a next-generation, integrated cell line development platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and commercial scalability.

time to read

1 min

May 2026

Bio Spectrum

Bio Spectrum

Eurofins Viracor unveils ExPECT anti-CD19 (obe-cel) CAR T-cell assay

Eurofins Viracor, a leader in advanced clinical diagnostics, has announced the launch of the ExPECT anti-CD19 (obe-cel) CAR T-cell assay, a cutting-edge solution designed to help clinicians monitor CAR T-cell therapy performance with validated precision and a quick turn-around-time for results.

time to read

1 min

May 2026

Listen

Translate

Share

-
+

Change font size